848C73F3-ABD7-47FD-BF70-FF29FBDF6F61
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- overall_survival_months
- 20.795006570302235
- age_years
- 48
- sex
- Female
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- E2F_TARGETS+0.514
- MYC_TARGETS_V1+0.513
- G2M_CHECKPOINT+0.493
- MYC_TARGETS_V2+0.486
- WNT_BETA_CATENIN_SIGNALING+0.476
- NOTCH_SIGNALING+0.348
- DNA_REPAIR+0.331
- MITOTIC_SPINDLE+0.303
- TGF_BETA_SIGNALING+0.283
- HEDGEHOG_SIGNALING+0.169
Top 10 suppressed
- ANGIOGENESIS-0.393
- INFLAMMATORY_RESPONSE-0.366
- MYOGENESIS-0.342
- COMPLEMENT-0.338
- COAGULATION-0.320
- KRAS_SIGNALING_DN-0.314
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.307
- BILE_ACID_METABOLISM-0.301
- IL6_JAK_STAT3_SIGNALING-0.294
- HYPOXIA-0.283
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | 4938761D-0762-4984-A399-BC036D6D2140 | — | — | 0.935 |
| 2 | SRR934853 | — | — | 0.935 |
| 3 | 0D1652B9-93F6-4D1A-BF06-B654663C92E3 | — | — | 0.915 |
| 4 | SRR934880 | — | — | 0.911 |
| 5 | SRR934765 | — | — | 0.909 |
| 6 | SRR934879 | — | — | 0.908 |
| 7 | 4FD9ED95-21E7-440D-AAA9-86DDDF12B37A | — | — | 0.904 |
| 8 | SRR934823 | — | — | 0.903 |
| 9 | 4FC69960-8EF2-49FE-A718-7004E99E00A8 | — | — | 0.903 |
| 10 | 4F62A177-D1C6-4829-A86E-7CA1D29421FC | — | — | 0.902 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 14 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| E2F_TARGETS | 0.514 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.513 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.493 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.486 | Idelalisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.476 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.348 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.331 | Idelalisib | — uncovered |
| MITOTIC_SPINDLE | 0.303 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.283 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.169 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.167 | Idelalisib | — uncovered |
| PEROXISOME | 0.075 | Idelalisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.069 | Remibrutinib | — uncovered |
| PROTEIN_SECRETION | 0.018 | Remibrutinib | — uncovered |